focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 10.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 7.00 (70.00%)
Open: 13.50
High: 13.50
Low: 13.50
Prev. Close: 13.50
HYG Live PriceLast checked at -
Seneca Growth Capital VCT is an Investment Trust

To provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value(s)

4 Apr 2024 07:00

Net Asset Value(s)

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

4 April 2024

Net asset value (“NAV”)

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios and announce an updated NAV for each of the share classes as at 31 March 2024.

B Shares

As at 31 March 2024, the unaudited NAV per B share was 63.7p.

This is a decrease of 7.0p from the audited NAV as at 31 December 2023 of 70.7p, predominantly as a result of AIM market volatility. The B share NAV as at 31 March 2024 incorporates changes in the bid prices of the B share pool’s AIM/AQSE quoted investments combined with the impact of income receivable and running costs incurred in the period. There have been no material changes in the valuations of any of the unlisted investments during the period from 31 December 2023 to the date of this announcement.

The unaudited NAV total return per B share (NAV plus cumulative dividends) as at 31 March 2024 was 78.7p.

Ordinary Shares

As at 31 March 2024, the unaudited NAV of an Ordinary share was 16.8p per share.

This is a decrease of 1.7p from the audited NAV as at 31 December 2023 of 18.5p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc and a decrease in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2024, shares in Scancell Holdings Plc were valued at 10.0p per share (31 December 2023: 10.5p) and shares in Arecor Therapeutics Plc were valued at 135.0p per share (31 December 2023: 180p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.

The unaudited NAV total return per Ordinary share (NAV plus cumulative dividends) as at 31 March 2024 was 90.1p.

The change in NAV for both the B Shares and Ordinary Shares represents a decrease of 0.1p per share, respectively, on the unaudited NAVs as at 20 March 2024, announced on 22 March 2024 and which was included in the Supplementary Prospectus published by the Company on 28 March 2024.

For the purposes of calculating the unaudited net asset value per share for both share classes, quoted investments are carried at closing bid prices as at 31 March 2024 and unquoted investments are carried at fair value as at 31 March 2024.

The number of B shares in issue at 31 March 2024 was 21,780,329 and the number of Ordinary shares was 8,115,376. Therefore, the total number of voting rights in the Company is 29,895,705.

The B share Offer by the Company remains open for the 2023/24 tax year until midday today, 4 April 2024 and shares will be allotted at the above latest published B share NAV.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
22nd Sep 200910:10 amRNSPortfolio Update
19th May 20099:42 amRNSIssue of Equity
15th May 20093:27 pmRNSIssue of Equity
12th May 20097:00 amRNSInterim Management Statement
6th May 20097:00 amRNSResults of AGM and Issue of Equity
30th Apr 20097:00 amRNSTotal Voting Rights
16th Apr 20097:00 amRNSAvailability of Annual Accounts and Offer Letter
9th Apr 20091:04 pmRNSIssue of Equity-Replacement
9th Apr 200912:41 pmRNSIssue of Equity
9th Apr 200912:39 pmRNSOffer to Shareholders
6th Apr 20094:32 pmRNSDirector's Dealings
2nd Apr 20097:00 amRNSAnnual Report & Accounts and Notice of AGM
19th Nov 20089:54 amRNSDirector's Dealings
14th Nov 20081:08 pmRNSInterim Management Statement
28th Aug 20087:00 amRNSInterim Results
1st Aug 20084:00 pmRNSIssue of Equity
22nd Jul 20083:11 pmRNSResult of AGM
30th May 20083:25 pmRNSIssue of Equity
15th May 20087:00 amRNSInterim Management Statement
1st May 200810:55 amRNSIssue of Equity
8th Apr 20085:18 pmRNSAnnual Information Update
3rd Apr 20083:42 pmRNSIssue of Equity
19th Mar 20085:02 pmRNSOffer to shareholders
19th Mar 20085:02 pmRNSAnnual Report and Accounts
14th Jan 20085:22 pmRNSUpdate letter to Shareholders
3rd Jul 20063:56 pmRNSCompany Secretary Change
10th May 20062:49 pmRNSPurchase of Own Securities
26th Apr 20062:50 pmRNSChange of Name
25th Apr 20065:02 pmRNSDirector's Shareholding
20th Apr 20067:01 amRNSBVCT Update
20th Apr 20067:00 amRNSResult of AGM
10th Apr 20063:23 pmRNSDirector/PDMR Shareholding
3rd Apr 20064:28 pmRNSDirector's Shareholding
29th Mar 20061:09 pmRNSAnnual Information Update
24th Mar 20064:19 pmRNSFinal Results
9th Mar 20067:00 amRNSInvestment Process & Strategy
11th Nov 20054:33 pmRNSDirectorate Change
4th Nov 20054:04 pmRNSResult of AGM
3rd Oct 200511:19 amRNSNotice of AGM
27th Sep 20057:00 amRNSInterim Results
1st Sep 20058:31 amRNSBoard Changes
16th Aug 20055:51 pmRNSVCT Status
16th Aug 20059:09 amRNSVCT Status
2nd Aug 200510:56 amRNSBoard Change
12th Jul 20055:04 pmRNSBoard Changes
29th Apr 200510:22 amRNSFinal Results
14th Feb 20054:02 pmRNSIssue of Equity
9th Feb 20052:20 pmRNSCancellation of Listing
8th Feb 200511:27 amRNSCancellation of Listing
28th Jan 20052:55 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.